IDEAS home Printed from https://ideas.repec.org/a/spr/pharmo/v6y2022i5d10.1007_s41669-022-00354-2.html
   My bibliography  Save this article

Cost-Effectiveness of Nintedanib for Patients with Progressive Fibrosing Interstitial Lung Disease (PF-ILD)

Author

Listed:
  • Lotte Westerink

    (University of Groningen, University Medical Center Groningen
    Asc Academics Inc.)

  • Jelmer Lennart Jens Nicolai

    (Boehringer Ingelheim International GmbH)

  • Maarten Jacobus Postma

    (University of Groningen, University Medical Center Groningen
    University of Groningen
    University of Groningen)

  • Job Frank Martien Boven

    (University of Groningen)

  • Cornelis Boersma

    (University of Groningen, University Medical Center Groningen
    Health-Ecore B.V.
    Open University)

Abstract

Objectives Progressive fibrosing interstitial lung disease (PF-ILD) is characterised by increased pulmonary fibrosis, lung function decline, acute exacerbations, decreased quality of life and increased mortality. Nintedanib may slow down disease progression, but long-term outcomes are unknown. We aimed to assess the cost-effectiveness of nintedanib in comparison to placebo, both on top of usual care in patients with PF-ILD. Methods An individual PF-ILD patient simulation model was created, using data and extrapolations from the nintedanib and placebo arms of the INBUILD trial. Clinical outcomes (mortality, exacerbations, lung transplants), economic outcomes (direct and indirect costs) and the cost-effectiveness of nintedanib over a 10-year time horizon were forecasted using the Netherlands as a case example. Disease progression was driven by lung function decline, with forced vital capacity (FVC) health states ranging from

Suggested Citation

  • Lotte Westerink & Jelmer Lennart Jens Nicolai & Maarten Jacobus Postma & Job Frank Martien Boven & Cornelis Boersma, 2022. "Cost-Effectiveness of Nintedanib for Patients with Progressive Fibrosing Interstitial Lung Disease (PF-ILD)," PharmacoEconomics - Open, Springer, vol. 6(5), pages 647-656, September.
    • Handle: RePEc:spr:pharmo:v:6:y:2022:i:5:d:10.1007_s41669-022-00354-2
    DOI: 10.1007/s41669-022-00354-2
    as

    Download full text from publisher

    File URL: http://link.springer.com/10.1007/s41669-022-00354-2
    File Function: Abstract
    Download Restriction: no
    File URL: https://libkey.io/10.1007/s41669-022-00354-2?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    References listed on IDEAS

    as
    1. Lotte Westerink & Jelmer L. J. Nicolai & Carl Samuelsen & Hans J. M. Smit & Pieter E. Postmus & Ingolf Griebsch & Maarten J. Postma, 2020. "Budget impact of sequential treatment with first-line afatinib versus first-line osimertinib in non-small-cell lung cancer patients with common EGFR mutations," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 21(6), pages 931-943, August.
    2. Matthijs Versteegh & Saskia Knies & Werner Brouwer, 2016. "From Good to Better: New Dutch Guidelines for Economic Evaluations in Healthcare," PharmacoEconomics, Springer, vol. 34(11), pages 1071-1074, November.
    3. C. Rinciog & M. Watkins & S. Chang & T. M. Maher & C. LeReun & D. Esser & A. Diamantopoulos, 2017. "A Cost-Effectiveness Analysis of Nintedanib in Idiopathic Pulmonary Fibrosis in the UK," PharmacoEconomics, Springer, vol. 35(4), pages 479-491, April.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. James F. O’Mahony, 2019. "Beneluxa: What are the Prospects for Collective Bargaining on Pharmaceutical Prices Given Diverse Health Technology Assessment Processes?," PharmacoEconomics, Springer, vol. 37(5), pages 627-630, May.
    2. Sebastian Himmler & Job Exel & Werner Brouwer, 2020. "Estimating the monetary value of health and capability well-being applying the well-being valuation approach," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 21(8), pages 1235-1244, November.
    3. Myles-Jay Linton & Paul Mark Mitchell & Hareth Al-Janabi & Michael Schlander & Jeff Richardson & Angelo Iezzi & Jasper Ubels & Joanna Coast, 2020. "Comparing the German Translation of the ICECAP-A Capability Wellbeing Measure to the Original English Version: Psychometric Properties across Healthy Samples and Seven Health Condition Groups," Applied Research in Quality of Life, Springer;International Society for Quality-of-Life Studies, vol. 15(3), pages 651-673, July.
    4. Elahe Khorasani & Majid Davari & Abbas Kebriaeezadeh & Farshad Fatemi & Ali Akbari Sari & Vida Varahrami, 2022. "A comprehensive review of official discount rates in guidelines of health economic evaluations over time: the trends and roots," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 23(9), pages 1577-1590, December.
    5. Petra Baji & Miklós Farkas & Ágota Dobos & Zsombor Zrubka & Levente Kovács & László Gulácsi & Márta Péntek, 2021. "Comparing the measurement properties of the ICECAP-A and ICECAP-O instruments in ages 50–70: a cross-sectional study on a representative sample of the Hungarian general population," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 22(9), pages 1453-1466, December.
    6. Hackert, Mariska Q.N. & Brouwer, Werner B.F. & Hoefman, Renske J. & van Exel, Job, 2019. "Views of older people in the Netherlands on wellbeing: A Q-methodology study," Social Science & Medicine, Elsevier, vol. 240(C).
    7. Robbin H Ophuis & Joran Lokkerbol & Juanita A Haagsma & Mickaël Hiligsmann & Silvia M A A Evers & Suzanne Polinder, 2018. "Value of information analysis of an early intervention for subthreshold panic disorder: Healthcare versus societal perspective," PLOS ONE, Public Library of Science, vol. 13(11), pages 1-13, November.
    8. Pieter van Baal & Meg Perry‐Duxbury & Pieter Bakx & Matthijs Versteegh & Eddy van Doorslaer & Werner Brouwer, 2019. "A cost‐effectiveness threshold based on the marginal returns of cardiovascular hospital spending," Health Economics, John Wiley & Sons, Ltd., vol. 28(1), pages 87-100, January.
    9. Tim A Kanters & Clazien A M Bouwmans & Naomi van der Linden & Siok Swan Tan & Leona Hakkaart-van Roijen, 2017. "Update of the Dutch manual for costing studies in health care," PLOS ONE, Public Library of Science, vol. 12(11), pages 1-11, November.
    10. Donna Rowen & Ismail Azzabi Zouraq & Helene Chevrou-Severac & Ben Hout, 2017. "International Regulations and Recommendations for Utility Data for Health Technology Assessment," PharmacoEconomics, Springer, vol. 35(1), pages 11-19, December.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:pharmo:v:6:y:2022:i:5:d:10.1007_s41669-022-00354-2. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.